Amid pandemic, London-based Thriva secures €4.5M funding to offer at-home health service

Once you get to know what’s going on inside your body, you can understand the impact of your lifestyle on your health and start to make small changes that add up to a healthier you. While there was no simple and convenient method to track it, Thriva, a London-based startup changed it through personalised home-kit. 

Raised €4.5 million!

In the latest development, the UK company has secured a £4 million (approx €4.5 million) extension to its Series A funding round from Berlin-based VC Target Global. The investment comes from Target Global’s new Early Stage Fund II. 

To date, the company has raised £11 million (approx €12.2 million). Existing investors include Guinness Asset Management and Pembroke VCT.

With this funding, the company intends to expand its at-home health service designed to help people stay on the front foot with their health and to continue putting better health in your hands. 

Hamish Grierson, co-founder, and CEO of Thriva said: 

“As the world faces unprecedented challenges posed by the coronavirus crisis, we have all been forced to view our health, and our mortality, in a new light.”

Processed over 115,000 tests! 

Thriva has processed over 115,000 test at-home blood tests since 2016 which have helped people keep track of what’s happening inside their bodies with 76% of Thriva users achieving an improvement in at least one of their biomarkers between tests.

Its at-home testing kits are processed by UKAS accredited laboratories and can analyse anything from indicators of heart disease and diabetes to vitamins and minerals and hormone function.

Hamish Grierson added: 

“We believe that now and in the near future, people will be taking a more proactive approach to their own health and wellbeing. Whilst we cannot protect ourselves entirely from the tragic effects of a global pandemic like COVID-19, this period may inspire people to invest in their general health for the long-term.”

100% year-on-year growth!

The company has now launched personalised health plans and high-quality supplements as well. As per the company claims, the business is scaling up its partnerships with hospitals and other healthcare provider looking to provide at-home testing to their patients and clients.

Notably, the company, which was founded by Hamish Grierson, Eliot Brooks, and Tom Livesey sees 100% year-on-year growth and has expanded its team significantly to 50 team members in the company’s London Headquarters.

Dr. Ricardo Schäfer – Partner at Target Global said: 

“When we first met the team behind Thriva, we were immediately hooked by their mission to allow people to take health into their own hands. Thriva has all the right ingredients to become one of those transforming category leaders we are seeking to back at Target Global.”

“We are witnessing a shift in consumer behavior towards an increasingly a proactive approach to health: people want to know what’s going on inside their bodies. Covid-19 is further accelerating this trend, which requires remote blood testing. Thriva is playing an essential role in providing a solution for increasing the test volume. We are excited to partner with Hamish, Eliot, and Tom at this pivotal point in time for the company.”

Main image credits: Thriva

Stay tuned to Silicon Canals for more European technology news

The post Amid pandemic, London-based Thriva secures €4.5M funding to offer at-home health service appeared first on Silicon Canals .

Startups – Silicon Canals

Thriva raises £4M from Target in an era when at-home blood testing is more crucial than ever

Thriva emerged in 2016 as an at-home blood-testing startup allowing people to check, for instance, cholesterol levels. In the era of a pandemic, however, at-home blood testing is about to become quite a big deal, alongside the general trend toward people proactively taking control of their health.

It has secured a £4 million extension to its Series A funding round from Berlin-based VC Target Global . The investment takes Thriva’s total funding to £11 million. The investment comes from Target Global’s new Early Stage Fund II and will top up the £6 million Series A raised in 2019. Existing investors include Guinness Asset Management and Pembroke VCT.

Thriva has processed more than 115,000 at-home blood tests since 2016. Interestingly, these customers actually use the information to improve their health, with 76% of Thriva users achieving an improvement in at least one of their biomarkers between tests.

The startup has also launched personalized health plans and high-quality supplements, scaling up its partnerships with hospitals and other healthcare providers.

Founded by Hamish Grierson, Eliot Brooks and Tom Livesey, it claims to be growing 100% year-on-year and has expanded its team to 50 members in the company’s London headquarters.

In a statement Grierson said: “As the world faces unprecedented challenges posed by the coronavirus crisis, we have all been forced to view our health, and our mortality, in a new light.”

Speaking to TechCrunch he added: “While there are other at-home testing companies, we don’t see them as directly competitive. Thriva isn’t a testing company. Our at-home blood tests are an important data point but they’re just the beginning of the long-term relationships we’re creating with our customers. To deliver on our mission of putting better health in your hands, we not only help people to keep track of what’s really happening inside their bodies, we actually help them to make positive changes that they can see the effects of over time.”

Dr. Ricardo Schäfer, partner at Target Global said: “When we first met the team behind Thriva, we were immediately hooked by their mission to allow people to take health into their own hands.”

Startups – TechCrunch